| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a4312a7b35719c8892121be20961aa1b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9262b9b8ff492cebb1eb14c1a6027fa1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_643b3e8f9dd8fccd938e975235b212df
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8facc764e86946aa04112134cecf52bd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_39c68430bcb778feae2ad4e9640ad0ca
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_07ead23f59e0c2e72c67c1c417d96ccf
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2558c9d25f80636c60e38d30f19977b9 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-3145
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-3233
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-3513 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-1131 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-113
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00 |
| filingDate |
2005-10-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2013-01-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c91d92685c7c84b191bf252e50d34b47
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_51b2da23198070bd8c30b25042cf3ace
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_138bf1aae425a87a268fc575683712d6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d41ebc56da235d13c3e4e0b8a7370586
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7103f5a81368a364c7383fffaec96c79 |
| publicationDate |
2013-01-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-8357664-B2 |
| titleOfInvention |
Antisense antiviral compound and method for treating influenza viral infection |
| abstract |
The invention provides antisense antiviral compounds and methods of their use and production in inhibition of growth of viruses of the Orthomyxoviridae family and in the treatment of a viral infection. The compounds are particularly useful in the treatment of influenza virus infection in a mammal. The antisense antiviral compounds are substantially uncharged morpholino oligonucleotides having 1) a nuclease resistant backbone, 2) 12-40 nucleotide bases, and 3) a targeting sequence of at least 12 bases in length that hybridizes to a target region selected from the following: a) the 5′ or 3′ terminal 25 bases of the negative sense viral RNA segment of Influenzavirus A, Influenzavirus B and Influenzavirus C; b) the terminal 25 bases of the 3′ terminus of the positive sense cRNA and; and c) the 50 bases surrounding the AUG start codon of an influenza viral mRNA. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9909123-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9777274-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10905782-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2020016280-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2014144442-A2 |
| priorityDate |
2004-10-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |